Turn Therapeutics' board accepted a sale to Merck at a minimal 6% premium, frustrating investors who believed in the long-term value of its CML drug. This move is seen as stripping optionality from shareholders, forcing a sale at a price that may not reflect the asset's full potential.
FDA Commissioner Macari is facing intense criticism, including from conservative media. This pressure may be compelling the agency to greenlight approvals, particularly for orphan drugs, to appease powerful patient advocacy groups and improve the agency's political standing ahead of potential leadership changes.
Market reaction to M&A is nuanced. Despite four deals, investor sentiment remained low because three targeted private companies and the fourth had a minimal premium. This highlights that for public market investors, the *type* and *premium* of an M&A deal are more important catalysts than the raw deal count.
Following the exit of controversial CBER director Vinay Prasad, the FDA approved several drugs that might have struggled under his tenure. This suggests a potential shift towards more regulatory flexibility, possibly influenced by political pressure ahead of midterm elections, creating opportunities for sponsors with controversial applications.
Contrary to typical risk-off behavior, the biotech index (XBI) is outperforming the S&P 500. It shows resilience on down days and outsized gains on up days. This indicates a persistent underlying investor demand for the sector, possibly due to its multi-year underperformance and maturing fundamentals.
Wave Life Sciences' stock was halved after its obesity drug failed to show significant overall body weight loss. Investors overlooked the clinically important reduction in visceral fat, which is more strongly linked to poor health outcomes. This highlights a market misunderstanding of key clinical endpoints.
Upcoming oral psoriasis drugs from J&J, Alumis, and Takeda offer efficacy close to injectables but with greater convenience. This strategy is not about stealing market share but about massive market expansion, targeting millions of patients using only topicals and potentially growing the market to over $40 billion.
Recent data readouts for companies like Sarepta show a pattern: a significant initial stock jump followed by a substantial pullback. This "sell the news" trend suggests a bearish market sentiment where investors are quick to take profits, lacking conviction in sustained upward momentum for early-stage assets.
Despite shedding over 22,000 jobs, large pharmaceutical companies are aggressively investing in external assets. This counterintuitive trend is driven by the urgent need to fill revenue gaps from a looming $300 billion patent cliff, signaling a major strategic shift from internal R&D to external innovation acquisition.